MDSC subtypes and CD39 expression on CD8 <sup>+</sup> T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Jiae Koh(Samsung Medical Center), Myung‐Ju Ahn(Samsung Medical Center)

European Journal of Immunology

June 8, 2020

10.1002/eji.202048534

Cited by 90

Related Papers

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

|Investigational New Drugs|2019|50

CpG oligodeoxynucleotides induce IL-8 expression in CD34+ cells via mitogen-activated protein kinase-dependent and NF-κB-independent pathways

|International Immunology|2005|40

Mutational status of <i>TP53</i> defines the efficacy of Wee1 inhibitor AZD1775 in <i>KRAS</i>-mutant non-small cell lung cancer

|Oncotarget|2017|40

Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray

|Cancer|2010|36

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer

|Investigational New Drugs|2022|8